DR. CONSTANTIN DASANU M.D., PH.D.
Prescription History 1922120708
Internal Medicine - Hematology & Oncology in Rancho Mirage, CA
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. CONSTANTIN DASANU M.D., PH.D., an active Hematology & Oncology specialist practicing in Rancho Mirage, CA. Our medical registry currently tracks 23 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 956 documented patient claims. Among these therapy options, the most frequently utilized medication is Prednisone, which accounts for 113 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other CA PrescribersVs. CA Avg |
|---|---|---|---|
| Prednisone | 113 | $8.61 | ▲ More than typical |
About Prednisone: Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Show more ▾ Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions. A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. In 2024, this provider wrote 113 Medicare prescriptions for Prednisone, about 2.8 times the volume of the typical California prescriber of this medication (40.3). Medicare paid an average of $8.61 per fill, versus $5.64 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 180.3 30-Day Fills standardized to 30-day supplies 5,255 Days of Medication total across all patients in 2024 | |||
| Abiraterone Acetate | 104 | $1,461.16 | ▲ More than typical |
About Abiraterone Acetate: This medication is used to treat prostate cancer. Show more ▾ Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children. An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER. In 2024, this provider wrote 104 Medicare prescriptions for Abiraterone Acetate, about 1.8 times the volume of the typical California prescriber of this medication (58.5). Medicare paid an average of $1,461.16 per fill, versus $1,101.95 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 108 30-Day Fills standardized to 30-day supplies 3,166 Days of Medication total across all patients in 2024 | |||
| Hydroxyurea | 88 | $13.33▼ below CA avg | ▲ More than typical |
About Hydroxyurea: This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Show more ▾ Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas). An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. In 2024, this provider wrote 88 Medicare prescriptions for Hydroxyurea, about 2.5 times the volume of the typical California prescriber of this medication (35.3). Medicare paid an average of $13.33 per fill, versus $28.53 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 101 30-Day Fills standardized to 30-day supplies 2,990 Days of Medication total across all patients in 2024 | |||
| Ondansetron OdtOndansetron | 66 | $32.10 | ▲ More than typical |
About Ondansetron Odt: This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. Show more ▾ It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting. A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. In 2024, this provider wrote 66 Medicare prescriptions for Ondansetron Odt, about 2.7 times the volume of the typical California prescriber of this medication (24.8). Medicare paid an average of $32.10 per fill, versus $13.40 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 70 30-Day Fills standardized to 30-day supplies 2,030 Days of Medication total across all patients in 2024 | |||
| EliquisApixaban | 65 | $748.56▼ below CA avg | ≈ Typical |
About Eliquis: Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. Show more ▾ With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood. An antithrombotic agent. In 2024, this provider wrote 65 Medicare prescriptions for Eliquis, about 89% of the volume of the typical California prescriber of this medication (72.9). Medicare paid an average of $748.56 per fill, versus $923.33 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 82 30-Day Fills standardized to 30-day supplies 2,444 Days of Medication total across all patients in 2024 | |||
| RevlimidLenalidomide | 51 | $15,754.93▼ below CA avg | ▲ More than typical |
About Revlimid: Lenalidomide is used to treat various types of cancers. Show more ▾ It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication. A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. In 2024, this provider wrote 51 Medicare prescriptions for Revlimid, about 1.7 times the volume of the typical California prescriber of this medication (30.7). Medicare paid an average of $15,754.93 per fill, versus $17,406.67 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 51 30-Day Fills standardized to 30-day supplies 1,428 Days of Medication total across all patients in 2024 | |||
| Dexamethasone | 48 | $17.33 | ▲ More than typical |
About Dexamethasone: Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. Show more ▾ It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions. An anti-inflammatory 9-fluoro-glucocorticoid. In 2024, this provider wrote 48 Medicare prescriptions for Dexamethasone, about 1.4 times the volume of the typical California prescriber of this medication (35.2). Medicare paid an average of $17.33 per fill, versus $13.93 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 67.1 30-Day Fills standardized to 30-day supplies 1,786 Days of Medication total across all patients in 2024 | |||
| Anastrozole | 43 | $16.10▼ below CA avg | ▼ Less than typical |
About Anastrozole: Anastrozole is used to treat breast cancer in women after menopause. Show more ▾ Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women. In 2024, this provider wrote 43 Medicare prescriptions for Anastrozole, about 63% of the volume of the typical California prescriber of this medication (68). Medicare paid an average of $16.10 per fill, versus $20.79 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 91 30-Day Fills standardized to 30-day supplies 2,730 Days of Medication total across all patients in 2024 | |||
| BrukinsaZanubrutinib | 42 | $12,602.14 | ▲ More than typical |
About Brukinsa: This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma). Show more ▾ Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. A Bruton tyrosine kinase (BTK) inhibitor for treatment of Waldenstrom macroglobulinemia. In 2024, this provider wrote 42 Medicare prescriptions for Brukinsa, about 1.4 times the volume of the typical California prescriber of this medication (30). Medicare paid an average of $12,602.14 per fill, versus $12,543.75 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 42 30-Day Fills standardized to 30-day supplies 1,260 Days of Medication total across all patients in 2024 | |||
| PomalystPomalidomide | 38 | $22,771.77 | ▲ More than typical |
About Pomalyst: Pomalidomide is used to treat certain types of cancers (such as multiple myeloma, Kaposi sarcoma). Show more ▾ It works by slowing or stopping the growth of cancer cells. An immunomodulator with antineoplastic and angiogenesis inhibitor activity. In 2024, this provider wrote 38 Medicare prescriptions for Pomalyst, about 1.4 times the volume of the typical California prescriber of this medication (26.7). Medicare paid an average of $22,771.77 per fill, versus $22,448.87 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 38 30-Day Fills standardized to 30-day supplies 1,064 Days of Medication total across all patients in 2024 | |||
| VenclextaVenetoclax | 36 | $7,149.14▼ below CA avg | ▲ More than typical |
About Venclexta: This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Show more ▾ Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells. A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion. In 2024, this provider wrote 36 Medicare prescriptions for Venclexta, about 1.6 times the volume of the typical California prescriber of this medication (22.5). Medicare paid an average of $7,149.14 per fill, versus $8,838.98 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 36 30-Day Fills standardized to 30-day supplies 1,029 Days of Medication total across all patients in 2024 | |||
| JakafiRuxolitinib Phosphate | 33 | $17,281.33 | ≈ Typical |
About Jakafi: This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). Show more ▾ It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system). In 2024, this provider wrote 33 Medicare prescriptions for Jakafi, about 1.2 times the volume of the typical California prescriber of this medication (28.2). Medicare paid an average of $17,281.33 per fill, versus $15,437.07 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 33 30-Day Fills standardized to 30-day supplies 990 Days of Medication total across all patients in 2024 | |||
| Tamoxifen Citrate | 32 | $11.74▼ below CA avg | ≈ Typical |
About Tamoxifen Citrate: Tamoxifen is used to treat breast cancer. Show more ▾ It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue. One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. In 2024, this provider wrote 32 Medicare prescriptions for Tamoxifen Citrate, about the same volume as the typical California prescriber of this medication (35.4). Medicare paid an average of $11.74 per fill, versus $24.93 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 70 30-Day Fills standardized to 30-day supplies 2,100 Days of Medication total across all patients in 2024 | |||
| XtandiEnzalutamide | 29 | $13,616.91 | ≈ Typical |
About Xtandi: Enzalutamide is used to treat prostate cancer. Show more ▾ This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer. An antineoplastic agent. In 2024, this provider wrote 29 Medicare prescriptions for Xtandi, about 86% of the volume of the typical California prescriber of this medication (33.6). Medicare paid an average of $13,616.91 per fill, versus $13,029.46 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 29 30-Day Fills standardized to 30-day supplies 870 Days of Medication total across all patients in 2024 | |||
| CalquenceAcalabrutinib Maleate | 29 | $15,304.99 | ▲ More than typical |
About Calquence: This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Show more ▾ Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors. Inhibits Bruton’s tyrosine kinase; has antineoplastic activity. In 2024, this provider wrote 29 Medicare prescriptions for Calquence, about 1.3 times the volume of the typical California prescriber of this medication (22.4). Medicare paid an average of $15,304.99 per fill, versus $13,810.38 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 29 30-Day Fills standardized to 30-day supplies 870 Days of Medication total across all patients in 2024 | |||
| Lenalidomide | 27 | $12,363.17▼ below CA avg | ▼ Less than typical |
About Lenalidomide: Lenalidomide is used to treat various types of cancers. Show more ▾ It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication. A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. In 2024, this provider wrote 27 Medicare prescriptions for Lenalidomide, about 70% of the volume of the typical California prescriber of this medication (38.8). Medicare paid an average of $12,363.17 per fill, versus $12,547.26 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 27 30-Day Fills standardized to 30-day supplies 756 Days of Medication total across all patients in 2024 | |||
| VyndamaxTafamidis | 21 | $22,952.88▼ below CA avg | ▼ Less than typical |
About Vyndamax: This medication is used to treat a certain type of heart failure (transthyretin-mediated amyloidosis). Show more ▾ It is used to help prevent the heart failure from getting worse and needing treatment in a hospital. Tafamidis works by slowing the buildup of a certain protein (amyloid fibrils) that causes heart problems. May be effective in treating transthyretin amyloid polyneuropathy. In 2024, this provider wrote 21 Medicare prescriptions for Vyndamax, about half the volume of the typical California prescriber of this medication (37.4). Medicare paid an average of $22,952.88 per fill, versus $25,182.09 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 21 30-Day Fills standardized to 30-day supplies 630 Days of Medication total across all patients in 2024 | |||
| Triamcinolone Acetonide | 20 | $19.60 | ▼ Less than typical |
About Triamcinolone Acetonide: This medication is used to treat a variety of skin conditions (such as eczema, dermatitis, allergies, rash). Show more ▾ Triamcinolone reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a medium- to strong-potency corticosteroid. The potency depends on the strength and the form that you use. For details on the potency of your product, ask your pharmacist. An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions. In 2024, this provider wrote 20 Medicare prescriptions for Triamcinolone Acetonide, about half the volume of the typical California prescriber of this medication (42.7). Medicare paid an average of $19.60 per fill, versus $10.03 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 24 30-Day Fills standardized to 30-day supplies 593 Days of Medication total across all patients in 2024 | |||
| Imatinib Mesylate | 19 | $115.26▼ below CA avg | ≈ Typical |
About Imatinib Mesylate: This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). Show more ▾ It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome). A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. In 2024, this provider wrote 19 Medicare prescriptions for Imatinib Mesylate, about 86% of the volume of the typical California prescriber of this medication (22). Medicare paid an average of $115.26 per fill, versus $905.12 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 19 30-Day Fills standardized to 30-day supplies 570 Days of Medication total across all patients in 2024 | |||
| Warfarin Sodium | 16 | $8.23▼ below CA avg | ▼ Less than typical |
About Warfarin Sodium: This medication is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and/or to prevent new clots from forming in your body. Show more ▾ Preventing harmful blood clots helps to reduce the risk of a stroke or heart attack. Conditions that increase your risk of developing blood clots include a certain type of irregular heart rhythm (atrial fibrillation), heart valve replacement, recent heart attack, and certain surgeries (such as hip/knee replacement). Warfarin is commonly called a "blood thinner," but the more correct term is "anticoagulant." It helps to keep blood flowing smoothly in your body by decreasing the amount of certain substances (clotting proteins) in your blood. An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. In 2024, this provider wrote 16 Medicare prescriptions for Warfarin Sodium, about a third of the volume of the typical California prescriber of this medication (39.9). Medicare paid an average of $8.23 per fill, versus $11.33 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 36 30-Day Fills standardized to 30-day supplies 1,080 Days of Medication total across all patients in 2024 | |||
| Levofloxacin | 13 | $4.35▼ below CA avg | ▼ Less than typical |
About Levofloxacin: Levofloxacin is used to treat a variety of bacterial infections. Show more ▾ This medication belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. The L-isomer of Ofloxacin. In 2024, this provider wrote 13 Medicare prescriptions for Levofloxacin, about half the volume of the typical California prescriber of this medication (27.2). Medicare paid an average of $4.35 per fill, versus $5.11 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 13 30-Day Fills standardized to 30-day supplies 113 Days of Medication total across all patients in 2024 | |||
| TagrissoOsimertinib Mesylate | 12 | $17,289.76 | ▼ Less than typical |
About Tagrisso: This medication is used to treat lung cancer. Show more ▾ Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors. An EGFR tyrosine kinase inhibitor. In 2024, this provider wrote 12 Medicare prescriptions for Tagrisso, about a third of the volume of the typical California prescriber of this medication (35.7). Medicare paid an average of $17,289.76 per fill, versus $16,840.72 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2024 | |||
| Letrozole | 11 | $22.52▼ below CA avg | ▼ Less than typical |
About Letrozole: This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Show more ▾ Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women. In 2024, this provider wrote 11 Medicare prescriptions for Letrozole, about a quarter of the volume of the typical California prescriber of this medication (49.4). Medicare paid an average of $22.52 per fill, versus $22.86 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 13 30-Day Fills standardized to 30-day supplies 390 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for DR. CONSTANTIN DASANU M.D., PH.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Hematology & Oncology prescribing approach at this Rancho Mirage, CA practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among CA prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
